High-dose cytosine arabinoside in the treatment of childhood malignancies.
D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002493:Central Nervous System Diseases / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D003561:Cytarabine / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004224:Diterpenes; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007223:Infant; D007945:Leukemia, Lymphoid / Q000188:drug therapy*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D008297:Male; D010198:Pancytopenia / Q000139:chemically induced; D012008:Recurrence; D000084562:Retinyl Esters; D014801:Vitamin A / Q000008:administration & dosage / Q000031:analogs & derivatives; D014839:Vomiting / Q000139:chemically induced
D004224:Diterpenes; D000084562:Retinyl Esters; D003561:Cytarabine; D014801:Vitamin A; C014794:retinol palmitate; D004317:Doxorubicin